董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eli D. Casdin | 男 | Director | 52 | 未披露 | 未持股 | 2025-09-17 |
| Emily Leproust | 女 | Director | 52 | 未披露 | 未持股 | 2025-09-17 |
| Keith Meister | 男 | Director | 52 | 未披露 | 未持股 | 2025-09-17 |
| Richard C. Pfenniger | 男 | Director | 69 | 未披露 | 未持股 | 2025-09-17 |
| Katherine Stueland | 女 | Chief Executive Officer and Director | 49 | 未披露 | 未持股 | 2025-09-17 |
| Thomas Fuchs | 男 | Director | -- | 未披露 | 未持股 | 2025-09-17 |
| Joshua Ruch | 男 | Director | 75 | 未披露 | 未持股 | 2025-09-17 |
| Jason Ryan | 男 | Chairman of the Board | 51 | 未披露 | 未持股 | 2025-09-17 |
| Keith Meister | 男 | Director | 51 | 未披露 | 未持股 | 2025-09-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Katherine Stueland | 女 | Chief Executive Officer and Director | 49 | 未披露 | 未持股 | 2025-09-17 |
| Kevin Feeley | 男 | Chief Financial Officer | 44 | 未披露 | 未持股 | 2025-09-17 |
| Bryan Dechairo | -- | Chief Operating Officer | 52 | 未披露 | 未持股 | 2025-09-17 |
董事简历
中英对照 | 中文 | 英文- Eli D. Casdin
-
Eli D. Casdin，自2020年7月起担任董事会成员，此前于2020年7月至2021年7月担任CMLS首席执行官。Casdin先生于2011年11月创立了Casdin Capital，LLC，一家专注于生命科学和医疗保健行业的投资公司，目前担任其首席投资官。Casdin先生分别自2022年4月和2024年3月起担任Standard BioTools和2seventy bio公司的董事会成员。Casdin先生还曾于2017年10月至2020年9月期间担任精密科学公司董事会成员，于2020年12月至2022年7月期间担任Absci公司董事会成员，于2021年2月至2022年10月期间担任Century Therapeutics，Inc.，于2020年1月至2022年11月期间担任EQRx，Inc.，于2021年12月至2024年1月期间担任SomaLogic，Inc.（曾于2020年12月至2021年9月期间担任CMLS II的首席执行官），并于2019年10月至2022年12月期间担任Tenaya Therapeutics, Inc.，TERM6，Tenaya Therapeutics，Inc.。Casdin先生拥有哥伦比亚商学院的工商管理硕士学位和哥伦比亚大学通识学院的学士学位。
Eli D. Casdin,has served as a member of Board since July 2020, and previously served as the Chief Executive Officer of CMLS from July 2020 to July 2021. Mr. Casdin founded Casdin Capital, LLC, an investment firm focused on the life sciences and healthcare industry, in November 2011, and currently serves as its Chief Investment Officer. Mr. Casdin has served on the boards of directors of Standard BioTools Inc. and 2seventy bio, Inc. since April 2022 and March 2024, respectively. Mr. Casdin has also served on the boards of directors of Exact Sciences Corp. from October 2017 to September 2020, Absci Corp. from December 2020 to July 2022, Century Therapeutics, Inc. from February 2021 to October 2022, EQRx, Inc. from January 2020 to November 2022, SomaLogic, Inc., from December 2021 to January 2024 (having previously served as the Chief Executive Officer of CMLS II from December 2020 to September 2021), and Tenaya Therapeutics, Inc., from October 2019 to December 2022. Mr. Casdin holds an M.B.A. from Columbia Business School and a B.S. degree from Columbia University School of General Studies. - Eli D. Casdin，自2020年7月起担任董事会成员，此前于2020年7月至2021年7月担任CMLS首席执行官。Casdin先生于2011年11月创立了Casdin Capital，LLC，一家专注于生命科学和医疗保健行业的投资公司，目前担任其首席投资官。Casdin先生分别自2022年4月和2024年3月起担任Standard BioTools和2seventy bio公司的董事会成员。Casdin先生还曾于2017年10月至2020年9月期间担任精密科学公司董事会成员，于2020年12月至2022年7月期间担任Absci公司董事会成员，于2021年2月至2022年10月期间担任Century Therapeutics，Inc.，于2020年1月至2022年11月期间担任EQRx，Inc.，于2021年12月至2024年1月期间担任SomaLogic，Inc.（曾于2020年12月至2021年9月期间担任CMLS II的首席执行官），并于2019年10月至2022年12月期间担任Tenaya Therapeutics, Inc.，TERM6，Tenaya Therapeutics，Inc.。Casdin先生拥有哥伦比亚商学院的工商管理硕士学位和哥伦比亚大学通识学院的学士学位。
- Eli D. Casdin,has served as a member of Board since July 2020, and previously served as the Chief Executive Officer of CMLS from July 2020 to July 2021. Mr. Casdin founded Casdin Capital, LLC, an investment firm focused on the life sciences and healthcare industry, in November 2011, and currently serves as its Chief Investment Officer. Mr. Casdin has served on the boards of directors of Standard BioTools Inc. and 2seventy bio, Inc. since April 2022 and March 2024, respectively. Mr. Casdin has also served on the boards of directors of Exact Sciences Corp. from October 2017 to September 2020, Absci Corp. from December 2020 to July 2022, Century Therapeutics, Inc. from February 2021 to October 2022, EQRx, Inc. from January 2020 to November 2022, SomaLogic, Inc., from December 2021 to January 2024 (having previously served as the Chief Executive Officer of CMLS II from December 2020 to September 2021), and Tenaya Therapeutics, Inc., from October 2019 to December 2022. Mr. Casdin holds an M.B.A. from Columbia Business School and a B.S. degree from Columbia University School of General Studies.
- Emily Leproust
-
Emily Leproust，自2020年9月起担任董事会成员。自2013年与他人共同创立Twist以来，Leproust博士一直担任生物技术公司Twist Bioscience Corp.的首席执行官。自2018年10月起，她还担任了Twist的董事会主席。在共同创立Twist之前，Leproust博士曾在分析仪器开发和制造公司安捷伦科技公司担任多个职位，最近一次是在2009年2月至2013年4月担任其应用和化学研发总监。她是Nuclear Threat Institute的董事会成员，Nuclear Threat Institute是一家非营利性全球安全组织，专注于减少危及人类的核威胁和生物威胁，并且是Petri的联合创始人，Petri是工程和生物学前沿初创企业的加速器。Leproust博士发表了30多篇经过同行评审的论文——其中许多是关于合成DNA应用的，并且是众多专利的作者。Leproust博士拥有休斯顿大学有机化学博士学位和里昂工业化学学院工业化学硕士学位。
Emily Leproust,has served as a member of Board since September 2020. Dr. Leproust has been Chief Executive Officer of Twist Bioscience Corp., a biotechnology company, since co-founding Twist in 2013. Since October 2018, she has also served as Chair of the board of directors for Twist. Prior to co-founding Twist, Dr. Leproust served in various positions at Agilent Technologies, Inc., an analytical instrumentation development and manufacturing company, most recently as its Director, Applications and Chemistry R&D from February 2009 to April 2013. She serves on the Board of Directors of the Nuclear Threat Institute, a nonprofit global security organization focused on reducing nuclear and biological threats imperiling humanity, and is a co-founder of Petri, an accelerator for start-ups at the forefront of engineering and biology. Dr. Leproust has published over 30 peer-reviewed papers – many on applications of synthetic DNA, and is the author of numerous patents. Dr. Leproust holds a Ph.D. in Organic Chemistry from the University of Houston and a M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry. - Emily Leproust，自2020年9月起担任董事会成员。自2013年与他人共同创立Twist以来，Leproust博士一直担任生物技术公司Twist Bioscience Corp.的首席执行官。自2018年10月起，她还担任了Twist的董事会主席。在共同创立Twist之前，Leproust博士曾在分析仪器开发和制造公司安捷伦科技公司担任多个职位，最近一次是在2009年2月至2013年4月担任其应用和化学研发总监。她是Nuclear Threat Institute的董事会成员，Nuclear Threat Institute是一家非营利性全球安全组织，专注于减少危及人类的核威胁和生物威胁，并且是Petri的联合创始人，Petri是工程和生物学前沿初创企业的加速器。Leproust博士发表了30多篇经过同行评审的论文——其中许多是关于合成DNA应用的，并且是众多专利的作者。Leproust博士拥有休斯顿大学有机化学博士学位和里昂工业化学学院工业化学硕士学位。
- Emily Leproust,has served as a member of Board since September 2020. Dr. Leproust has been Chief Executive Officer of Twist Bioscience Corp., a biotechnology company, since co-founding Twist in 2013. Since October 2018, she has also served as Chair of the board of directors for Twist. Prior to co-founding Twist, Dr. Leproust served in various positions at Agilent Technologies, Inc., an analytical instrumentation development and manufacturing company, most recently as its Director, Applications and Chemistry R&D from February 2009 to April 2013. She serves on the Board of Directors of the Nuclear Threat Institute, a nonprofit global security organization focused on reducing nuclear and biological threats imperiling humanity, and is a co-founder of Petri, an accelerator for start-ups at the forefront of engineering and biology. Dr. Leproust has published over 30 peer-reviewed papers – many on applications of synthetic DNA, and is the author of numerous patents. Dr. Leproust holds a Ph.D. in Organic Chemistry from the University of Houston and a M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry.
- Keith Meister
-
Keith Meister，自2022年1月起担任董事会成员，此前于2020年7月至2021年7月担任CMLS董事会主席。他于2010年12月创立了Corvex Management LP，这是一家总部位于纽约的投资管理公司，自成立以来一直担任其管理合伙人和首席投资官。从2003年到2010年，梅斯特先生曾担任Carl Icahn的主要投资工具Icahn Enterprises L.P.（纳斯达克：IEP）的首席执行官、随后的首席执行官兼首席执行官兼Vice Chairman of the Board。此外，Meister先生此前曾于2020年12月至2021年9月担任CM Life Sciences II Inc.的董事长，并于2021年1月至2021年12月担任CM Life Sciences III Inc.的董事长。梅斯特先生还担任全球酒店和娱乐公司MGM Resorts International（NYSE：MGM）及其附属公司BetMGM、出租制服和工作场所用品供应商Vestis（NYSE：VSTS）以及DNA测序和基于阵列技术的全球领导者Illumina, Inc.，Inc.（纳斯达克：ILMN）的董事会成员。梅斯特先生此前曾在其职业生涯中担任过许多其他上市公司的董事会成员，其中包括百胜集团。Brands Inc.（NYSE：YUM）、威廉姆斯公司（NYSE：WMB）、ADT，Inc.（NYSE：ADT）、Ralcorp Holdings，Inc.和Motorola, Inc.（现称摩托罗拉解决方案公司，NYSE：MSI/Motorola Mobility，Inc.）。他是哈莱姆儿童区董事会主席，也是美国自然历史博物馆董事会成员。梅斯特先生拥有哈佛学院政府学士学位，并以优异成绩毕业。
Keith Meister,has served as a member of Board since January 2022, and previously served as the Chairman of the Board of CMLS from July 2020 to July 2021. He founded Corvex Management LP, a New York based investment manager, in December 2010 and since its inception has served as its Managing Partner and Chief Investment Officer. From 2003 to 2010, Mr. Meister served as Chief Executive Officer and then Principal Executive Officer and Vice Chairman of the Board of Icahn Enterprises L.P. (Nasdaq: IEP), the primary investment vehicle for Carl Icahn. In addition, Mr. Meister previously served as Chairman of CM Life Sciences II Inc. from December 2020 to September 2021 and CM Life Sciences III Inc. from January 2021 to December 2021. Mr. Meister also serves on the Board of Directors of MGM Resorts International (NYSE: MGM), a global hospitality and entertainment company, and its affiliate BetMGM, Vestis (NYSE: VSTS), a provider of rental uniforms and workplace supplies and Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies. Mr. Meister has previously served on the Board of Directors of numerous other public companies in his career, including Yum! Brands Inc. (NYSE: YUM), The Williams Companies, Inc. (NYSE: WMB), ADT, Inc. (NYSE: ADT), Ralcorp Holdings, Inc. and Motorola, Inc. (now Motorola Solutions, Inc., NYSE: MSI/Motorola Mobility, Inc.). He is Chairman of the board of the Harlem Children's Zone and also serves on the board of trustees of the American Museum of Natural History. Mr. Meister holds a B.A. degree in government from Harvard College where he graduated cum laude. - Keith Meister，自2022年1月起担任董事会成员，此前于2020年7月至2021年7月担任CMLS董事会主席。他于2010年12月创立了Corvex Management LP，这是一家总部位于纽约的投资管理公司，自成立以来一直担任其管理合伙人和首席投资官。从2003年到2010年，梅斯特先生曾担任Carl Icahn的主要投资工具Icahn Enterprises L.P.（纳斯达克：IEP）的首席执行官、随后的首席执行官兼首席执行官兼Vice Chairman of the Board。此外，Meister先生此前曾于2020年12月至2021年9月担任CM Life Sciences II Inc.的董事长，并于2021年1月至2021年12月担任CM Life Sciences III Inc.的董事长。梅斯特先生还担任全球酒店和娱乐公司MGM Resorts International（NYSE：MGM）及其附属公司BetMGM、出租制服和工作场所用品供应商Vestis（NYSE：VSTS）以及DNA测序和基于阵列技术的全球领导者Illumina, Inc.，Inc.（纳斯达克：ILMN）的董事会成员。梅斯特先生此前曾在其职业生涯中担任过许多其他上市公司的董事会成员，其中包括百胜集团。Brands Inc.（NYSE：YUM）、威廉姆斯公司（NYSE：WMB）、ADT，Inc.（NYSE：ADT）、Ralcorp Holdings，Inc.和Motorola, Inc.（现称摩托罗拉解决方案公司，NYSE：MSI/Motorola Mobility，Inc.）。他是哈莱姆儿童区董事会主席，也是美国自然历史博物馆董事会成员。梅斯特先生拥有哈佛学院政府学士学位，并以优异成绩毕业。
- Keith Meister,has served as a member of Board since January 2022, and previously served as the Chairman of the Board of CMLS from July 2020 to July 2021. He founded Corvex Management LP, a New York based investment manager, in December 2010 and since its inception has served as its Managing Partner and Chief Investment Officer. From 2003 to 2010, Mr. Meister served as Chief Executive Officer and then Principal Executive Officer and Vice Chairman of the Board of Icahn Enterprises L.P. (Nasdaq: IEP), the primary investment vehicle for Carl Icahn. In addition, Mr. Meister previously served as Chairman of CM Life Sciences II Inc. from December 2020 to September 2021 and CM Life Sciences III Inc. from January 2021 to December 2021. Mr. Meister also serves on the Board of Directors of MGM Resorts International (NYSE: MGM), a global hospitality and entertainment company, and its affiliate BetMGM, Vestis (NYSE: VSTS), a provider of rental uniforms and workplace supplies and Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies. Mr. Meister has previously served on the Board of Directors of numerous other public companies in his career, including Yum! Brands Inc. (NYSE: YUM), The Williams Companies, Inc. (NYSE: WMB), ADT, Inc. (NYSE: ADT), Ralcorp Holdings, Inc. and Motorola, Inc. (now Motorola Solutions, Inc., NYSE: MSI/Motorola Mobility, Inc.). He is Chairman of the board of the Harlem Children's Zone and also serves on the board of trustees of the American Museum of Natural History. Mr. Meister holds a B.A. degree in government from Harvard College where he graduated cum laude.
- Richard C. Pfenniger
-
Richard C. Pfenniger，自2022年4月起担任董事会成员。Pfenniger先生还是一位私人投资者，曾担任多家公司的执行官，包括在2003年至2011年期间担任初级保健医生和执业管理服务提供商Continucare Corporation的首席执行官兼总裁，并在2002年至2011年期间担任Continucare Corporation的董事会主席。此前，Pfenniger先生曾于1997年至2003年担任Whitman Education Group，Inc.的首席执行官和副主席。在加入惠特曼之前，他曾于1994年至1997年担任IVAX的首席运营官，并于1989年至1994年担任IVAX Corporation的高级副总裁-法律事务和总法律顾问。在此之前，他从事私人执业法律工作。Pfenniger先生目前担任生物制药和医学诊断公司OPKO保健，Inc.，发展阶段制药公司Cocrystal Pharma, Inc.和数据驱动的绩效营销公司Fluent, Inc.的董事。他还担任受托人的Vice Chairman of the Board以及菲利普和帕特里夏·弗罗斯特科学博物馆执行委员会成员。Pfenniger先生此前曾担任医疗器械公司Asensus Surgical, Inc.、开发心血管疾病新疗法的临床阶段再生医学公司BioCardia，Inc.、为健康行业的生育和静脉护理领域的患者和提供者提供产品和服务的私营专科医疗保健服务公司IntegraMed America，Inc.、企业教育和培训公司GP战略教育，Inc.、投资管理和财务咨询公司Wright Investors‘Services Holdings，Inc.、美国静脉诊所和投资管理和财务咨询公司Wright Investors’Services Holdings，Inc.的董事。
Richard C. Pfenniger,has served as a member of Board since April 2022. Mr. Pfenniger is also a private investor who has served as an executive officer of several companies, including as Chief Executive Officer and President of Continucare Corporation, a provider of primary care physician and practice management services, from 2003 until 2011, where he also served as Chairman of the Board of Directors of Continucare Corporation from 2002 until 2011. Previously, Mr. Pfenniger served as the Chief Executive Officer and Vice Chairman of Whitman Education Group, Inc. from 1997 through 2003. Prior to joining Whitman, he served as the Chief Operating Officer of IVAX from 1994 to 1997, and, from 1989 to 1994, he served as the Senior Vice President-Legal Affairs and General Counsel of IVAX Corporation. Prior thereto he was engaged in the private practice of law. Mr. Pfenniger currently serves as a director of OPKO Health, Inc., a biopharmaceutical and medical diagnostics company, Cocrystal Pharma, Inc., a development stage pharmaceutical company, and Fluent, Inc., a data driven performance marketing company. He also serves as the Vice Chairman of the Board of Trustees and as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. Mr. Pfenniger previously served as a director of Asensus Surgical, Inc., a medical device company, BioCardia, Inc., clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, IntegraMed America, Inc., a private specialty healthcare services company offering products and services to patients and providers in the fertility and vein care segments of the health industry, GP Strategies, Inc., a corporate education and training company, and Wright Investors' Services Holdings, Inc., an investment management and financial advisory firm, Vein Clinics of America and Wright Investors' Services Holdings, Inc., an investment management and financial advisory firm. - Richard C. Pfenniger，自2022年4月起担任董事会成员。Pfenniger先生还是一位私人投资者，曾担任多家公司的执行官，包括在2003年至2011年期间担任初级保健医生和执业管理服务提供商Continucare Corporation的首席执行官兼总裁，并在2002年至2011年期间担任Continucare Corporation的董事会主席。此前，Pfenniger先生曾于1997年至2003年担任Whitman Education Group，Inc.的首席执行官和副主席。在加入惠特曼之前，他曾于1994年至1997年担任IVAX的首席运营官，并于1989年至1994年担任IVAX Corporation的高级副总裁-法律事务和总法律顾问。在此之前，他从事私人执业法律工作。Pfenniger先生目前担任生物制药和医学诊断公司OPKO保健，Inc.，发展阶段制药公司Cocrystal Pharma, Inc.和数据驱动的绩效营销公司Fluent, Inc.的董事。他还担任受托人的Vice Chairman of the Board以及菲利普和帕特里夏·弗罗斯特科学博物馆执行委员会成员。Pfenniger先生此前曾担任医疗器械公司Asensus Surgical, Inc.、开发心血管疾病新疗法的临床阶段再生医学公司BioCardia，Inc.、为健康行业的生育和静脉护理领域的患者和提供者提供产品和服务的私营专科医疗保健服务公司IntegraMed America，Inc.、企业教育和培训公司GP战略教育，Inc.、投资管理和财务咨询公司Wright Investors‘Services Holdings，Inc.、美国静脉诊所和投资管理和财务咨询公司Wright Investors’Services Holdings，Inc.的董事。
- Richard C. Pfenniger,has served as a member of Board since April 2022. Mr. Pfenniger is also a private investor who has served as an executive officer of several companies, including as Chief Executive Officer and President of Continucare Corporation, a provider of primary care physician and practice management services, from 2003 until 2011, where he also served as Chairman of the Board of Directors of Continucare Corporation from 2002 until 2011. Previously, Mr. Pfenniger served as the Chief Executive Officer and Vice Chairman of Whitman Education Group, Inc. from 1997 through 2003. Prior to joining Whitman, he served as the Chief Operating Officer of IVAX from 1994 to 1997, and, from 1989 to 1994, he served as the Senior Vice President-Legal Affairs and General Counsel of IVAX Corporation. Prior thereto he was engaged in the private practice of law. Mr. Pfenniger currently serves as a director of OPKO Health, Inc., a biopharmaceutical and medical diagnostics company, Cocrystal Pharma, Inc., a development stage pharmaceutical company, and Fluent, Inc., a data driven performance marketing company. He also serves as the Vice Chairman of the Board of Trustees and as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. Mr. Pfenniger previously served as a director of Asensus Surgical, Inc., a medical device company, BioCardia, Inc., clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, IntegraMed America, Inc., a private specialty healthcare services company offering products and services to patients and providers in the fertility and vein care segments of the health industry, GP Strategies, Inc., a corporate education and training company, and Wright Investors' Services Holdings, Inc., an investment management and financial advisory firm, Vein Clinics of America and Wright Investors' Services Holdings, Inc., an investment management and financial advisory firm.
- Katherine Stueland
-
收购完成后，Katherine Stueland自2022年4月起担任首席执行官和董事会成员。收购之前，Stueland女士是Legacy GeneDX的总裁兼首席执行官。在加入Legacy GeneDX之前，Stueland女士于2016年10月至2021年6月在生物技术公司Invitae Corporation担任首席商务官，并于2013年11月至2016年10月在Invitae Corporation担任传播和投资者关系主管，在此期间，她帮助Invitae Corporation从一家私营公司过渡到一家上市公司。Studeland女士此前曾于2013年1月至2013年12月在技术公司Vivo Communications担任负责人，并于2009年9月至2012年6月在生物技术公司Dendreon Corporation担任传播和投资者关系副总裁。斯图兰女士此前还曾担任Rivkin中心的董事会成员，该中心是一家致力于治疗和预防女性癌症的非营利组织。斯图兰德女士获得了俄亥俄州迈阿密大学的英语语言和文学学士学位。
Katherine Stueland,has served as Chief Executive Officer and a member of Board since April 2022, following the completion of the Acquisition. Prior to the Acquisition, Ms. Stueland was the President and Chief Executive Officer of Legacy GeneDx. Prior to joining Legacy GeneDx, Ms. Stueland served as the Chief Commercial Officer at Invitae Corporation, a biotechnology company, from October 2016 to June 2021 and as the Head of Communications and Investor Relations at Invitae Corporation from November 2013 to October 2016, during which time she helped Invitae Corporation transition from a private to a public company. Ms. Stueland previously served as the Principal at Vivo Communications, a technology company, from January 2013 to December 2013, and as the Vice President of Communications and Investor Relations at Dendreon Corporation, a biotechnology company, from September 2009 to June 2012. Ms. Stueland also previously served on the board of the Rivkin Center, a non-profit organization dedicated to the treatment and prevention of cancer in women. Ms. Stueland earned a B.S. in English language and literature from Miami University of Ohio. - 收购完成后，Katherine Stueland自2022年4月起担任首席执行官和董事会成员。收购之前，Stueland女士是Legacy GeneDX的总裁兼首席执行官。在加入Legacy GeneDX之前，Stueland女士于2016年10月至2021年6月在生物技术公司Invitae Corporation担任首席商务官，并于2013年11月至2016年10月在Invitae Corporation担任传播和投资者关系主管，在此期间，她帮助Invitae Corporation从一家私营公司过渡到一家上市公司。Studeland女士此前曾于2013年1月至2013年12月在技术公司Vivo Communications担任负责人，并于2009年9月至2012年6月在生物技术公司Dendreon Corporation担任传播和投资者关系副总裁。斯图兰女士此前还曾担任Rivkin中心的董事会成员，该中心是一家致力于治疗和预防女性癌症的非营利组织。斯图兰德女士获得了俄亥俄州迈阿密大学的英语语言和文学学士学位。
- Katherine Stueland,has served as Chief Executive Officer and a member of Board since April 2022, following the completion of the Acquisition. Prior to the Acquisition, Ms. Stueland was the President and Chief Executive Officer of Legacy GeneDx. Prior to joining Legacy GeneDx, Ms. Stueland served as the Chief Commercial Officer at Invitae Corporation, a biotechnology company, from October 2016 to June 2021 and as the Head of Communications and Investor Relations at Invitae Corporation from November 2013 to October 2016, during which time she helped Invitae Corporation transition from a private to a public company. Ms. Stueland previously served as the Principal at Vivo Communications, a technology company, from January 2013 to December 2013, and as the Vice President of Communications and Investor Relations at Dendreon Corporation, a biotechnology company, from September 2009 to June 2012. Ms. Stueland also previously served on the board of the Rivkin Center, a non-profit organization dedicated to the treatment and prevention of cancer in women. Ms. Stueland earned a B.S. in English language and literature from Miami University of Ohio.
- Thomas Fuchs
-
Thomas Fuchs在礼来公司（“礼来”）担任高级副总裁兼首席AI官，在那里他为药物发现、临床试验、制造、商业活动和内部职能提供人工智能（“AI”）计划的愿景、战略方向和全面领导。他还确定、构建和管理人工智能和机器学习解决方案，以帮助礼来向世界各地的患者提供药物。在加入礼来公司之前，他是西奈山人工智能与人类健康领域的院长和首任系主任，西奈山Digital Health的Hasso Plattner研究所所长，以及西奈山伊坎医学院人工智能与计算病理学方面的杰出教授Barbara T. Murphy。在西奈山之前，Fuchs博士曾在纪念斯隆凯特琳癌症中心、NASA喷气推进实验室和加州理工学院任职，并创立了三家公司，包括Paige AI。Fuchs博士拥有苏黎世联邦理工学院机器学习博士学位和奥地利格拉茨技术大学技术数学硕士学位。
Thomas Fuchs,serves as SVP and Chief AI Officer at Eli Lilly and Company ("Lilly"), where he provides vision, strategic direction, and overall leadership of artificial intelligence ("AI") initiatives for drug discovery, clinical trials, manufacturing, commercial activities, and internal functions. He also identifies, builds and manages AI and machine learning solutions to help Lilly deliver medicines to patients around the world. Before joining Lilly, he was the Dean and inaugural Department Chair for AI and Human Health at Mount Sinai, Director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the endowed Barbara T. Murphy Professor for AI and Computational Pathology at the Icahn School of Medicine at Mount Sinai. Prior to Mount Sinai, Dr. Fuchs held positions at Memorial Sloan Kettering Cancer Center, NASA's Jet Propulsion Laboratory and the California Institute of Technology, and founded three companies, including Paige AI. Dr. Fuchs holds a doctoral degree in machine learning from ETH Zurich and a master's degree in technical mathematics from Graz Technical University in Austria. - Thomas Fuchs在礼来公司（“礼来”）担任高级副总裁兼首席AI官，在那里他为药物发现、临床试验、制造、商业活动和内部职能提供人工智能（“AI”）计划的愿景、战略方向和全面领导。他还确定、构建和管理人工智能和机器学习解决方案，以帮助礼来向世界各地的患者提供药物。在加入礼来公司之前，他是西奈山人工智能与人类健康领域的院长和首任系主任，西奈山Digital Health的Hasso Plattner研究所所长，以及西奈山伊坎医学院人工智能与计算病理学方面的杰出教授Barbara T. Murphy。在西奈山之前，Fuchs博士曾在纪念斯隆凯特琳癌症中心、NASA喷气推进实验室和加州理工学院任职，并创立了三家公司，包括Paige AI。Fuchs博士拥有苏黎世联邦理工学院机器学习博士学位和奥地利格拉茨技术大学技术数学硕士学位。
- Thomas Fuchs,serves as SVP and Chief AI Officer at Eli Lilly and Company ("Lilly"), where he provides vision, strategic direction, and overall leadership of artificial intelligence ("AI") initiatives for drug discovery, clinical trials, manufacturing, commercial activities, and internal functions. He also identifies, builds and manages AI and machine learning solutions to help Lilly deliver medicines to patients around the world. Before joining Lilly, he was the Dean and inaugural Department Chair for AI and Human Health at Mount Sinai, Director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the endowed Barbara T. Murphy Professor for AI and Computational Pathology at the Icahn School of Medicine at Mount Sinai. Prior to Mount Sinai, Dr. Fuchs held positions at Memorial Sloan Kettering Cancer Center, NASA's Jet Propulsion Laboratory and the California Institute of Technology, and founded three companies, including Paige AI. Dr. Fuchs holds a doctoral degree in machine learning from ETH Zurich and a master's degree in technical mathematics from Graz Technical University in Austria.
- Joshua Ruch
-
Joshua Ruch，2007年起担任Verenium 的董事；在Verenium 与Celunol的合并前，他从2004年12月起，担任Celunol的董事。他是一家他于1981年联合创立的投资和风险投资公司管理公司-Rho Capital Partners, Inc.的董事长和首席执行官。创立Rho Capital Partners, Inc.前，他曾在Salomon Brothers从事投资银行业务。他持有以色列理工学院的电气工程学士学位和Harvard 商学院的工商管理硕士学位。他还是许多私有企业的一位董事。
Joshua Ruch has served as a director of Verenium since 2007 and prior to Verenium’s merger with Celunol, was a director of Celunol since December 2004. Mr. Ruch is the Chairman and Chief Executive Officer of Rho Capital Partners, Inc., an investment and venture capital management company, which he co-founded in 1981. Prior to founding Rho, Mr. Ruch was employed in investment banking at Salomon Brothers. Mr. Ruch received a B.S. degree in electrical engineering from the Israel Institute of Technology Technion and an M.B.A. from the Harvard Business School. Mr. Ruch is also a director of a number of private companies. - Joshua Ruch，2007年起担任Verenium 的董事；在Verenium 与Celunol的合并前，他从2004年12月起，担任Celunol的董事。他是一家他于1981年联合创立的投资和风险投资公司管理公司-Rho Capital Partners, Inc.的董事长和首席执行官。创立Rho Capital Partners, Inc.前，他曾在Salomon Brothers从事投资银行业务。他持有以色列理工学院的电气工程学士学位和Harvard 商学院的工商管理硕士学位。他还是许多私有企业的一位董事。
- Joshua Ruch has served as a director of Verenium since 2007 and prior to Verenium’s merger with Celunol, was a director of Celunol since December 2004. Mr. Ruch is the Chairman and Chief Executive Officer of Rho Capital Partners, Inc., an investment and venture capital management company, which he co-founded in 1981. Prior to founding Rho, Mr. Ruch was employed in investment banking at Salomon Brothers. Mr. Ruch received a B.S. degree in electrical engineering from the Israel Institute of Technology Technion and an M.B.A. from the Harvard Business School. Mr. Ruch is also a director of a number of private companies.
- Jason Ryan
-
Jason Ryan自2021年4月起担任Singular Genomics Systems, Inc.董事会成员。在加入董事会之前，Ryan先生于2019年1月至2020年10月担任Magenta Therapeutics, Inc.MGTA的首席运营和财务官。在加入Magenta Therapeutics, Inc.之前，Ryan先生曾担任Foundation Medicine, Inc.（从2015年3月到2018年11月成为Roche Holdings, Inc.的全资子公司）的首席财务官。在担任Foundation Medicine, Inc.的首席财务官之前，Ryan先生曾担任Foundation Medicine的各种其他财务职务。在加入Foundation Medicine, Inc.之前，Ryan先生领导各种其他生命科学公司的财务和战略规划职能，包括Taligen Therapeutics, Inc.， Codon Devices Inc.和Genomics Collaborative, Inc.。从2020年4月到2020年10月，Ryan先生还担任ArcherDX, Inc.（被Invitae Corporation（纽约证券交易所代码：NVTA）收购）的董事会成员。他的职业生涯始于Deloitte & Touche。他持有Bates College的经济学学士学位和Babson College的工商管理硕士学位，并在马萨诸塞州获得注册会计师证书。
Jason Ryan,has served as a member of Singular Genomics Systems, Inc. Board of Directors since April 2021. Prior to joining the Board of Directors, Mr. Ryan served as Chief Operating and Financial Officer of Magenta Therapeutics, Inc. (Nasdaq: MGTA) from January 2019 to October 2020. Prior to joining Magenta Therapeutics, Inc., Mr. Ryan previously served as Chief Financial Officer of Foundation Medicine, Inc., which became a wholly owned subsidiary of Roche Holdings, Inc., from March 2015 to November 2018. Prior to his position as Chief Financial Officer of Foundation Medicine, Inc., Mr. Ryan served in various other finance roles at Foundation Medicine. Prior to joining Foundation Medicine, Inc., Mr. Ryan led the finance and strategic planning functions of various other life science companies including Taligen Therapeutics, Inc., Codon Devices Inc. and Genomics Collaborative, Inc. Mr. Ryan currently serves as Executive Chairman of GeneDx (formerly Sema4) (Nasdaq: WGS) and Chairman of the Board of SomaLogic, Inc. (Nasdaq: SLGC) and previously served on the board of directors of ArcherDX, Inc., which was acquired by Invitae Corporation, from April 2020 to October 2020. He began his career at Deloitte & Touche. Mr. Ryan holds a B.S. in Economics from Bates College, holds an M.B.A. from Babson College and earned a C.P.A. in Massachusetts. - Jason Ryan自2021年4月起担任Singular Genomics Systems, Inc.董事会成员。在加入董事会之前，Ryan先生于2019年1月至2020年10月担任Magenta Therapeutics, Inc.MGTA的首席运营和财务官。在加入Magenta Therapeutics, Inc.之前，Ryan先生曾担任Foundation Medicine, Inc.（从2015年3月到2018年11月成为Roche Holdings, Inc.的全资子公司）的首席财务官。在担任Foundation Medicine, Inc.的首席财务官之前，Ryan先生曾担任Foundation Medicine的各种其他财务职务。在加入Foundation Medicine, Inc.之前，Ryan先生领导各种其他生命科学公司的财务和战略规划职能，包括Taligen Therapeutics, Inc.， Codon Devices Inc.和Genomics Collaborative, Inc.。从2020年4月到2020年10月，Ryan先生还担任ArcherDX, Inc.（被Invitae Corporation（纽约证券交易所代码：NVTA）收购）的董事会成员。他的职业生涯始于Deloitte & Touche。他持有Bates College的经济学学士学位和Babson College的工商管理硕士学位，并在马萨诸塞州获得注册会计师证书。
- Jason Ryan,has served as a member of Singular Genomics Systems, Inc. Board of Directors since April 2021. Prior to joining the Board of Directors, Mr. Ryan served as Chief Operating and Financial Officer of Magenta Therapeutics, Inc. (Nasdaq: MGTA) from January 2019 to October 2020. Prior to joining Magenta Therapeutics, Inc., Mr. Ryan previously served as Chief Financial Officer of Foundation Medicine, Inc., which became a wholly owned subsidiary of Roche Holdings, Inc., from March 2015 to November 2018. Prior to his position as Chief Financial Officer of Foundation Medicine, Inc., Mr. Ryan served in various other finance roles at Foundation Medicine. Prior to joining Foundation Medicine, Inc., Mr. Ryan led the finance and strategic planning functions of various other life science companies including Taligen Therapeutics, Inc., Codon Devices Inc. and Genomics Collaborative, Inc. Mr. Ryan currently serves as Executive Chairman of GeneDx (formerly Sema4) (Nasdaq: WGS) and Chairman of the Board of SomaLogic, Inc. (Nasdaq: SLGC) and previously served on the board of directors of ArcherDX, Inc., which was acquired by Invitae Corporation, from April 2020 to October 2020. He began his career at Deloitte & Touche. Mr. Ryan holds a B.S. in Economics from Bates College, holds an M.B.A. from Babson College and earned a C.P.A. in Massachusetts.
- Keith Meister
-
Keith Meister，自2022年1月起担任董事会成员，此前从2020年7月至2021年7月担任CMLS董事会主席。他于2010年12月创立了Corvex Management LP（一家总部位于纽约的投资管理公司），自公司成立以来一直担任其管理合伙人和首席投资官。从2003年到2010年，他担任Icahn Enterprises L.P.（纳斯达克股票代码：IEP）的首席执行官、首席执行官和董事会副主席，这是卡尔·伊坎的主要投资工具。此外，他曾担任CM Life Sciences II Inc.（2020年12月至2021年9月）和CM Life Sciences III Inc.（2021年1月至2021年12月）的董事长。他还担任全球酒店和娱乐公司MGM Resorts International（纽约证券交易所代码：MGM）及其附属公司BetMGM， Vestis（纽约证券交易所代码：VSTS）（租赁制服和工作场所用品供应商）和Illumina， Inc.（纳斯达克代码：ILMN）的董事会成员，Illumina, Inc.（纳斯达克代码：ILMN）是DNA测序和阵列技术的全球领导者。在他的职业生涯中，Meister先生曾担任许多其他上市公司的董事会成员，包括YUM! Brands, Inc.（纽约证券交易所代码：YUM）， The Williams Companies, Inc.（纽约证券交易所代码：WMB）， ADT, Inc.（纽约证券交易所代码：ADT）， Ralcorp Holdings, Inc.和Motorola， Inc.（现在的Motorola Solutions， Inc.，纽约证券交易所代码：MSI/Motorola Mobility， Inc）。他是哈莱姆儿童区董事会主席，也是美国自然历史博物馆董事会成员。他持有Harvard College的政府学士学位，并以优异成绩毕业。
Keith Meister,has served as a member of Board since January 2022, and previously served as the Chairman of the Board of CMLS from July 2020 to July 2021. He founded Corvex Management LP, a New York based investment manager, in December 2010 and since its inception has served as its Managing Partner and Chief Investment Officer. From 2003 to 2010, Mr. Meister served as Chief Executive Officer and then Principal Executive Officer and Vice Chairman of the Board of Icahn Enterprises L.P. (Nasdaq: IEP), the primary investment vehicle for Carl Icahn. In addition, Mr. Meister previously served as Chairman of CM Life Sciences II Inc. from December 2020 to September 2021 and CM Life Sciences III Inc. from January 2021 to December 2021. Mr. Meister also serves on the Board of Directors of MGM Resorts International (NYSE: MGM), a global hospitality and entertainment company, and its affiliate BetMGM, Vestis (NYSE: VSTS), a provider of rental uniforms and workplace supplies and Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies. Mr. Meister has previously served on the Board of Directors of numerous other public companies in his career, including Yum! Brands Inc. (NYSE: YUM), The Williams Companies, Inc. (NYSE: WMB), ADT, Inc. (NYSE: ADT), Ralcorp Holdings, Inc. and Motorola, Inc. (now Motorola Solutions, Inc., NYSE: MSI/Motorola Mobility, Inc.). He is Chairman of the board of the Harlem Children's Zone and also serves on the board of trustees of the American Museum of Natural History. Mr. Meister holds a B.A. degree in government from Harvard College where he graduated cum laude. - Keith Meister，自2022年1月起担任董事会成员，此前从2020年7月至2021年7月担任CMLS董事会主席。他于2010年12月创立了Corvex Management LP（一家总部位于纽约的投资管理公司），自公司成立以来一直担任其管理合伙人和首席投资官。从2003年到2010年，他担任Icahn Enterprises L.P.（纳斯达克股票代码：IEP）的首席执行官、首席执行官和董事会副主席，这是卡尔·伊坎的主要投资工具。此外，他曾担任CM Life Sciences II Inc.（2020年12月至2021年9月）和CM Life Sciences III Inc.（2021年1月至2021年12月）的董事长。他还担任全球酒店和娱乐公司MGM Resorts International（纽约证券交易所代码：MGM）及其附属公司BetMGM， Vestis（纽约证券交易所代码：VSTS）（租赁制服和工作场所用品供应商）和Illumina， Inc.（纳斯达克代码：ILMN）的董事会成员，Illumina, Inc.（纳斯达克代码：ILMN）是DNA测序和阵列技术的全球领导者。在他的职业生涯中，Meister先生曾担任许多其他上市公司的董事会成员，包括YUM! Brands, Inc.（纽约证券交易所代码：YUM）， The Williams Companies, Inc.（纽约证券交易所代码：WMB）， ADT, Inc.（纽约证券交易所代码：ADT）， Ralcorp Holdings, Inc.和Motorola， Inc.（现在的Motorola Solutions， Inc.，纽约证券交易所代码：MSI/Motorola Mobility， Inc）。他是哈莱姆儿童区董事会主席，也是美国自然历史博物馆董事会成员。他持有Harvard College的政府学士学位，并以优异成绩毕业。
- Keith Meister,has served as a member of Board since January 2022, and previously served as the Chairman of the Board of CMLS from July 2020 to July 2021. He founded Corvex Management LP, a New York based investment manager, in December 2010 and since its inception has served as its Managing Partner and Chief Investment Officer. From 2003 to 2010, Mr. Meister served as Chief Executive Officer and then Principal Executive Officer and Vice Chairman of the Board of Icahn Enterprises L.P. (Nasdaq: IEP), the primary investment vehicle for Carl Icahn. In addition, Mr. Meister previously served as Chairman of CM Life Sciences II Inc. from December 2020 to September 2021 and CM Life Sciences III Inc. from January 2021 to December 2021. Mr. Meister also serves on the Board of Directors of MGM Resorts International (NYSE: MGM), a global hospitality and entertainment company, and its affiliate BetMGM, Vestis (NYSE: VSTS), a provider of rental uniforms and workplace supplies and Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies. Mr. Meister has previously served on the Board of Directors of numerous other public companies in his career, including Yum! Brands Inc. (NYSE: YUM), The Williams Companies, Inc. (NYSE: WMB), ADT, Inc. (NYSE: ADT), Ralcorp Holdings, Inc. and Motorola, Inc. (now Motorola Solutions, Inc., NYSE: MSI/Motorola Mobility, Inc.). He is Chairman of the board of the Harlem Children's Zone and also serves on the board of trustees of the American Museum of Natural History. Mr. Meister holds a B.A. degree in government from Harvard College where he graduated cum laude.
高管简历
中英对照 | 中文 | 英文- Katherine Stueland
收购完成后，Katherine Stueland自2022年4月起担任首席执行官和董事会成员。收购之前，Stueland女士是Legacy GeneDX的总裁兼首席执行官。在加入Legacy GeneDX之前，Stueland女士于2016年10月至2021年6月在生物技术公司Invitae Corporation担任首席商务官，并于2013年11月至2016年10月在Invitae Corporation担任传播和投资者关系主管，在此期间，她帮助Invitae Corporation从一家私营公司过渡到一家上市公司。Studeland女士此前曾于2013年1月至2013年12月在技术公司Vivo Communications担任负责人，并于2009年9月至2012年6月在生物技术公司Dendreon Corporation担任传播和投资者关系副总裁。斯图兰女士此前还曾担任Rivkin中心的董事会成员，该中心是一家致力于治疗和预防女性癌症的非营利组织。斯图兰德女士获得了俄亥俄州迈阿密大学的英语语言和文学学士学位。
Katherine Stueland,has served as Chief Executive Officer and a member of Board since April 2022, following the completion of the Acquisition. Prior to the Acquisition, Ms. Stueland was the President and Chief Executive Officer of Legacy GeneDx. Prior to joining Legacy GeneDx, Ms. Stueland served as the Chief Commercial Officer at Invitae Corporation, a biotechnology company, from October 2016 to June 2021 and as the Head of Communications and Investor Relations at Invitae Corporation from November 2013 to October 2016, during which time she helped Invitae Corporation transition from a private to a public company. Ms. Stueland previously served as the Principal at Vivo Communications, a technology company, from January 2013 to December 2013, and as the Vice President of Communications and Investor Relations at Dendreon Corporation, a biotechnology company, from September 2009 to June 2012. Ms. Stueland also previously served on the board of the Rivkin Center, a non-profit organization dedicated to the treatment and prevention of cancer in women. Ms. Stueland earned a B.S. in English language and literature from Miami University of Ohio.- 收购完成后，Katherine Stueland自2022年4月起担任首席执行官和董事会成员。收购之前，Stueland女士是Legacy GeneDX的总裁兼首席执行官。在加入Legacy GeneDX之前，Stueland女士于2016年10月至2021年6月在生物技术公司Invitae Corporation担任首席商务官，并于2013年11月至2016年10月在Invitae Corporation担任传播和投资者关系主管，在此期间，她帮助Invitae Corporation从一家私营公司过渡到一家上市公司。Studeland女士此前曾于2013年1月至2013年12月在技术公司Vivo Communications担任负责人，并于2009年9月至2012年6月在生物技术公司Dendreon Corporation担任传播和投资者关系副总裁。斯图兰女士此前还曾担任Rivkin中心的董事会成员，该中心是一家致力于治疗和预防女性癌症的非营利组织。斯图兰德女士获得了俄亥俄州迈阿密大学的英语语言和文学学士学位。
- Katherine Stueland,has served as Chief Executive Officer and a member of Board since April 2022, following the completion of the Acquisition. Prior to the Acquisition, Ms. Stueland was the President and Chief Executive Officer of Legacy GeneDx. Prior to joining Legacy GeneDx, Ms. Stueland served as the Chief Commercial Officer at Invitae Corporation, a biotechnology company, from October 2016 to June 2021 and as the Head of Communications and Investor Relations at Invitae Corporation from November 2013 to October 2016, during which time she helped Invitae Corporation transition from a private to a public company. Ms. Stueland previously served as the Principal at Vivo Communications, a technology company, from January 2013 to December 2013, and as the Vice President of Communications and Investor Relations at Dendreon Corporation, a biotechnology company, from September 2009 to June 2012. Ms. Stueland also previously served on the board of the Rivkin Center, a non-profit organization dedicated to the treatment and prevention of cancer in women. Ms. Stueland earned a B.S. in English language and literature from Miami University of Ohio.
- Kevin Feeley
Kevin Feeley，自2022年8月起担任首席财务官。Feeley先生此前曾于2022年5月至2022年8月担任运营高级副总裁兼GeneDX负责人。在加入之前，Feeley先生于2016年至2022年期间担任OPKO保健诊断部门的首席财务官，收购前该部门包括BioReference Laboratories，Inc.和Legacy GeneDX。Feeley此前曾在Reckitt Benckiser担任美国财务总监，该公司是一家专注于健康、卫生和营养品牌的全球消费品包装公司。他此前还曾在公共专业制药公司Bausch Health公司领导SEC的报告工作，并在毕马威会计师事务所（KPMG LLP）的审计实践中度过了十二年，与大型跨国制药公司密切合作。Feeley先生是一名注册会计师，拥有詹姆斯麦迪逊大学的工商管理硕士学位。
Kevin Feeley,has served as Chief Financial Officer since August 2022. Mr. Feeley previously served as Senior Vice President of Operations and Head of GeneDx from May 2022 to August 2022. Prior to joining, Mr. Feeley served as Chief Financial Officer of OPKO Health's diagnostics division from 2016 to 2022, which included BioReference Laboratories, Inc. and Legacy GeneDx, prior to the Acquisition. Mr. Feeley previously served as the U.S. Controller at Reckitt Benckiser, a global consumer packaged goods company focused on health, hygiene, and nutrition brands. He also previously led SEC reporting at Bausch Health Companies, a public specialty pharmaceutical company, and spent twelve years in the audit practice of KPMG LLP working closely with large multinational pharmaceutical companies. Mr. Feeley is a certified public accountant and holds a BBA from James Madison University.- Kevin Feeley，自2022年8月起担任首席财务官。Feeley先生此前曾于2022年5月至2022年8月担任运营高级副总裁兼GeneDX负责人。在加入之前，Feeley先生于2016年至2022年期间担任OPKO保健诊断部门的首席财务官，收购前该部门包括BioReference Laboratories，Inc.和Legacy GeneDX。Feeley此前曾在Reckitt Benckiser担任美国财务总监，该公司是一家专注于健康、卫生和营养品牌的全球消费品包装公司。他此前还曾在公共专业制药公司Bausch Health公司领导SEC的报告工作，并在毕马威会计师事务所（KPMG LLP）的审计实践中度过了十二年，与大型跨国制药公司密切合作。Feeley先生是一名注册会计师，拥有詹姆斯麦迪逊大学的工商管理硕士学位。
- Kevin Feeley,has served as Chief Financial Officer since August 2022. Mr. Feeley previously served as Senior Vice President of Operations and Head of GeneDx from May 2022 to August 2022. Prior to joining, Mr. Feeley served as Chief Financial Officer of OPKO Health's diagnostics division from 2016 to 2022, which included BioReference Laboratories, Inc. and Legacy GeneDx, prior to the Acquisition. Mr. Feeley previously served as the U.S. Controller at Reckitt Benckiser, a global consumer packaged goods company focused on health, hygiene, and nutrition brands. He also previously led SEC reporting at Bausch Health Companies, a public specialty pharmaceutical company, and spent twelve years in the audit practice of KPMG LLP working closely with large multinational pharmaceutical companies. Mr. Feeley is a certified public accountant and holds a BBA from James Madison University.
- Bryan Dechairo
Bryan Dechairo，自2025年1月起担任首席运营官。Dechairo博士此前于2021年6月至2024年12月担任分子诊断公司Sherlock Biosciences，Inc.的总裁兼首席执行官，并于2017年8月至2021年4月担任基因检测和精准医疗公司Myriad Genetics, Inc.的高级管理人员兼发展执行副总裁。Dechairo博士此前曾于2023年3月至2024年12月担任BioCARIT Group NV的董事会成员。Dechairo博士拥有伦敦大学学院的人类遗传学博士学位和加州大学伯克利分校的综合生物学学士学位。
Bryan Dechairo,has served as Chief Operating Officer since January 2025. Dr. Dechairo previously served as President and Chief Executive Officer of Sherlock Biosciences, Inc., a molecular diagnostics company, from June 2021 to December 2024, and as Officer and Executive Vice President of Development at Myriad Genetics, Inc., a genetic testing and precision medicine company, from August 2017 to April 2021. Dr. Dechairo previously served on the Board of Directors of Biocartis Group NV from March 2023 to December 2024. Dr. Dechairo holds a Ph.D. in Human Genetics from the University College of London and a B.A. in Integrative Biology from the University of California, Berkeley.- Bryan Dechairo，自2025年1月起担任首席运营官。Dechairo博士此前于2021年6月至2024年12月担任分子诊断公司Sherlock Biosciences，Inc.的总裁兼首席执行官，并于2017年8月至2021年4月担任基因检测和精准医疗公司Myriad Genetics, Inc.的高级管理人员兼发展执行副总裁。Dechairo博士此前曾于2023年3月至2024年12月担任BioCARIT Group NV的董事会成员。Dechairo博士拥有伦敦大学学院的人类遗传学博士学位和加州大学伯克利分校的综合生物学学士学位。
- Bryan Dechairo,has served as Chief Operating Officer since January 2025. Dr. Dechairo previously served as President and Chief Executive Officer of Sherlock Biosciences, Inc., a molecular diagnostics company, from June 2021 to December 2024, and as Officer and Executive Vice President of Development at Myriad Genetics, Inc., a genetic testing and precision medicine company, from August 2017 to April 2021. Dr. Dechairo previously served on the Board of Directors of Biocartis Group NV from March 2023 to December 2024. Dr. Dechairo holds a Ph.D. in Human Genetics from the University College of London and a B.A. in Integrative Biology from the University of California, Berkeley.